13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

197 trials found

diseases per page:

Showing 1 to 10 of 197 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05658484 (ClinicalTrials.gov)	April 13, 2023	12/12/2022	A Study of Dimethyl Fumarate(DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in Chi ...	A Multicenter, Postmarketing Study of Dimethyl Fumarate(Tecfidera; BG00012) in Relapsing Forms of Mu ...	Multiple Sclerosis	Drug: Dimethyl fumarate	Biogen	NULL	Not yet recruiting	18 Years	65 Years	All	60	Phase 4	NULL
2	NCT05658497 (ClinicalTrials.gov)	January 20, 2023	12/12/2022	Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)	Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry	Multiple Sclerosis	Drug: Diroximel Fumarate;Drug: Avonex;Biological: Tysabri;Drug: Dimethyl Fumarate	Biogen	NULL	Not yet recruiting	N/A	N/A	Female	454		NULL
3	NCT05417269 (ClinicalTrials.gov)	April 12, 2022	1/6/2022	IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study	A Phase I/II Dose Escalation/Adaptive Design Study to Evaluate the Safety and Efficacy of IMCY-0141 ...	Multiple Sclerosis, Relapsing-Remitting	Drug: IMCY-0141;Drug: Placebo;Drug: Dimethyl Fumarate	Imcyse SA	NULL	Recruiting	18 Years	45 Years	All	150	Phase 1/Phase 2	Moldova, Republic of
4	EUCTR2019-001341-40-LV (EUCTR)	02/09/2021	28/07/2021	An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS tran ...	A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiven ...	Multiple sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclero ...	Trade Name: Kesimpta Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	550	Phase 3	United States;Portugal;Estonia;Saudi Arabia;Slovakia;Greece;Spain;Lebanon;Russian Federation;Italy;S ...
5	NCT04925778 (ClinicalTrials.gov)	June 30, 2021	8/6/2021	Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® F ...	An Open-label, Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched ...	Relapsing Remitting Multiple Sclerosis	Drug: monomethyl fumarate	Banner Life Sciences LLC	NULL	Withdrawn	18 Years	N/A	All	0		NULL
6	EUCTR2020-005752-38-DE (EUCTR)	18/03/2021	19/01/2021	An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants wit ...	An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants wit ...	secondary progressive multiple sclerosis (SPMS);Therapeutic area: Diseases [C] - Nervous System Dise ...	Trade Name: Mayzent 2 mg Filmtabletten Product Name: Mayzent 2 mg Filmtabletten Product Code: BAF312A INN ...	Novartis Pharma GmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 4	Germany
7	NCT04756687 (ClinicalTrials.gov)	March 10, 2021	12/2/2021	Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfid ...	A Retrospective Analysis in Real World on Lymphocyte Reconstitution After Lymphopenia in Patients Tr ...	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Drug: Dimethyl fumarate	Biogen	NULL	Completed	18 Years	N/A	All	1507		France
8	NCT04468165 (ClinicalTrials.gov)	February 23, 2021	8/7/2020	Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate(Sclera® or Marovarex ®, Hikma) ...	Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate(Sclera® or Marovarex ®, Hikma) ...	Relapsing Remitting Multiple Sclerosis	Drug: Dimethyl Fumarate (DMF)	Hikma Pharmaceuticals LLC	NULL	Active, not recruiting	18 Years	N/A	All	155		Algeria;Egypt;Jordan
9	EUCTR2019-001341-40-IT (EUCTR)	09/09/2020	19/05/2021	An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS tran ...	A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiven ...	Multiple sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclero ...	Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	550	Phase 3	United States;Portugal;Saudi Arabia;Slovakia;Greece;Spain;Lebanon;Russian Federation;Italy;Switzerla ...
10	EUCTR2019-001341-40-PT (EUCTR)	15/06/2020	31/03/2020	An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS tran ...	A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiven ...	Multiple sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclero ...	Trade Name: Arzerra Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	550	Phase 3	United States;Portugal;Saudi Arabia;Slovakia;Greece;Spain;Lebanon;Russian Federation;Italy;Switzerla ...

First Previous1 2 3 4 5…20Next Last